Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia

F. Maranta, L. Tondi, E. Agricola, A. Margonato, O. Rimoldi, Paolo G. Camici

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ivabradine is an effective treatment for angina in patients with stable coronary artery disease (CAD) and for heart failure. Experiments in a canine model have shown that ivabradine reduces both acute left ventricular (LV) dysfunction and post-ischaemic stunning. Aim of this study was to investigate the effect of ivabradine on LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. Fifteen patients with ejection fraction >40 % and heart rate >70 bpm were enrolled. After pharmacologic washout, echocardiography was performed at rest, at peak treadmill exercise and during recovery until return to baseline. After 2 weeks of ivabradine (7.5 mg bid) stress echocardiography was repeated at the same workload achieved during washout. Peak global and segmental (ischaemic vs. remote normal segments) LV longitudinal strain (LS) was assessed by 2D speckle tracking analysis. At washout, LS was significantly impaired in ischaemic compared to remote segments at peak stress and for several minutes during recovery. After ivabradine a smaller, albeit still significant, impairment of LS in ischaemic segments was observed at peak whilst no difference with remote segments was present during recovery. Furthermore, the average global LS value improved significantly after treatment. In conclusion, ivabradine reduces both acute LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. We hypothesise that this mechanism might contribute to reduce chronic LV dysfunction in patients with CAD. In this setting the drug might limit the development of hibernating myocardium which is believed to result from repeated episodes of ischaemia and stunning.

Original languageEnglish
Article number55
JournalBasic Research in Cardiology
Volume110
Issue number6
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

ivabradine
Myocardial Stunning
Ischemia
Left Ventricular Dysfunction
Exercise
Coronary Artery Disease
Stress Echocardiography
Workload
Echocardiography
Canidae
Myocardium
Heart Failure
Heart Rate

Keywords

  • Coronary artery disease
  • Echocardiography
  • Ivabradine
  • Longitudinal strain
  • Myocardial ischaemia
  • Post-ischaemic stunning

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. / Maranta, F.; Tondi, L.; Agricola, E.; Margonato, A.; Rimoldi, O.; Camici, Paolo G.

In: Basic Research in Cardiology, Vol. 110, No. 6, 55, 01.11.2015.

Research output: Contribution to journalArticle

@article{044a2addcba743269fecc224555771b8,
title = "Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia",
abstract = "Ivabradine is an effective treatment for angina in patients with stable coronary artery disease (CAD) and for heart failure. Experiments in a canine model have shown that ivabradine reduces both acute left ventricular (LV) dysfunction and post-ischaemic stunning. Aim of this study was to investigate the effect of ivabradine on LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. Fifteen patients with ejection fraction >40 {\%} and heart rate >70 bpm were enrolled. After pharmacologic washout, echocardiography was performed at rest, at peak treadmill exercise and during recovery until return to baseline. After 2 weeks of ivabradine (7.5 mg bid) stress echocardiography was repeated at the same workload achieved during washout. Peak global and segmental (ischaemic vs. remote normal segments) LV longitudinal strain (LS) was assessed by 2D speckle tracking analysis. At washout, LS was significantly impaired in ischaemic compared to remote segments at peak stress and for several minutes during recovery. After ivabradine a smaller, albeit still significant, impairment of LS in ischaemic segments was observed at peak whilst no difference with remote segments was present during recovery. Furthermore, the average global LS value improved significantly after treatment. In conclusion, ivabradine reduces both acute LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. We hypothesise that this mechanism might contribute to reduce chronic LV dysfunction in patients with CAD. In this setting the drug might limit the development of hibernating myocardium which is believed to result from repeated episodes of ischaemia and stunning.",
keywords = "Coronary artery disease, Echocardiography, Ivabradine, Longitudinal strain, Myocardial ischaemia, Post-ischaemic stunning",
author = "F. Maranta and L. Tondi and E. Agricola and A. Margonato and O. Rimoldi and Camici, {Paolo G.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s00395-015-0511-8",
language = "English",
volume = "110",
journal = "Basic Research in Cardiology",
issn = "0300-8428",
publisher = "D. Steinkopff-Verlag",
number = "6",

}

TY - JOUR

T1 - Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia

AU - Maranta, F.

AU - Tondi, L.

AU - Agricola, E.

AU - Margonato, A.

AU - Rimoldi, O.

AU - Camici, Paolo G.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Ivabradine is an effective treatment for angina in patients with stable coronary artery disease (CAD) and for heart failure. Experiments in a canine model have shown that ivabradine reduces both acute left ventricular (LV) dysfunction and post-ischaemic stunning. Aim of this study was to investigate the effect of ivabradine on LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. Fifteen patients with ejection fraction >40 % and heart rate >70 bpm were enrolled. After pharmacologic washout, echocardiography was performed at rest, at peak treadmill exercise and during recovery until return to baseline. After 2 weeks of ivabradine (7.5 mg bid) stress echocardiography was repeated at the same workload achieved during washout. Peak global and segmental (ischaemic vs. remote normal segments) LV longitudinal strain (LS) was assessed by 2D speckle tracking analysis. At washout, LS was significantly impaired in ischaemic compared to remote segments at peak stress and for several minutes during recovery. After ivabradine a smaller, albeit still significant, impairment of LS in ischaemic segments was observed at peak whilst no difference with remote segments was present during recovery. Furthermore, the average global LS value improved significantly after treatment. In conclusion, ivabradine reduces both acute LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. We hypothesise that this mechanism might contribute to reduce chronic LV dysfunction in patients with CAD. In this setting the drug might limit the development of hibernating myocardium which is believed to result from repeated episodes of ischaemia and stunning.

AB - Ivabradine is an effective treatment for angina in patients with stable coronary artery disease (CAD) and for heart failure. Experiments in a canine model have shown that ivabradine reduces both acute left ventricular (LV) dysfunction and post-ischaemic stunning. Aim of this study was to investigate the effect of ivabradine on LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. Fifteen patients with ejection fraction >40 % and heart rate >70 bpm were enrolled. After pharmacologic washout, echocardiography was performed at rest, at peak treadmill exercise and during recovery until return to baseline. After 2 weeks of ivabradine (7.5 mg bid) stress echocardiography was repeated at the same workload achieved during washout. Peak global and segmental (ischaemic vs. remote normal segments) LV longitudinal strain (LS) was assessed by 2D speckle tracking analysis. At washout, LS was significantly impaired in ischaemic compared to remote segments at peak stress and for several minutes during recovery. After ivabradine a smaller, albeit still significant, impairment of LS in ischaemic segments was observed at peak whilst no difference with remote segments was present during recovery. Furthermore, the average global LS value improved significantly after treatment. In conclusion, ivabradine reduces both acute LV dysfunction and stunning in patients with CAD and exercise-inducible ischaemia. We hypothesise that this mechanism might contribute to reduce chronic LV dysfunction in patients with CAD. In this setting the drug might limit the development of hibernating myocardium which is believed to result from repeated episodes of ischaemia and stunning.

KW - Coronary artery disease

KW - Echocardiography

KW - Ivabradine

KW - Longitudinal strain

KW - Myocardial ischaemia

KW - Post-ischaemic stunning

UR - http://www.scopus.com/inward/record.url?scp=84942762928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942762928&partnerID=8YFLogxK

U2 - 10.1007/s00395-015-0511-8

DO - 10.1007/s00395-015-0511-8

M3 - Article

C2 - 26419678

AN - SCOPUS:84942762928

VL - 110

JO - Basic Research in Cardiology

JF - Basic Research in Cardiology

SN - 0300-8428

IS - 6

M1 - 55

ER -